Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Q Li, Y Tie, A Alu, X Ma, H Shi - Signal transduction and targeted …, 2023 - nature.com
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

[HTML][HTML] Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials

B Goel, AK Tiwari, RK Pandey, AP Singh, S Kumar… - Translational …, 2022 - Elsevier
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma

R Wilken, MS Veena, MB Wang, ES Srivatsan - Molecular cancer, 2011 - Springer
Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa plant,
commonly known as turmeric. Curcumin has been used extensively in Ayurvedic medicine …

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

NY Lee, Q Zhang, DG Pfister, J Kim, AS Garden… - The lancet …, 2012 - thelancet.com
Background We aimed to improve the outcomes for locoregionally advanced
nasopharyngeal carcinoma by testing the feasibility and safety of the addition of …

Clinical update on cancer: molecular oncology of head and neck cancer

Y Suh, I Amelio, T Guerrero Urbano, M Tavassoli - Cell death & disease, 2014 - nature.com
Head and neck cancers encompass a heterogeneous group of tumours that, in general, are
biologically aggressive in nature. These cancers remain difficult to treat and treatment can …

Optical image-guided surgery—where do we stand?

S Keereweer, JDF Kerrebijn, PBAA Van Driel… - Molecular Imaging and …, 2011 - Springer
In cancer surgery, intra-operative assessment of the tumor-free margin, which is critical for
the prognosis of the patient, relies on the visual appearance and palpation of the tumor …

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

AM Jubb, AL Harris - The lancet oncology, 2010 - thelancet.com
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has
antiangiogenic activity and improves progression-free survival in many solid malignancies …

[HTML][HTML] EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling

S Sato, S Vasaikar, A Eskaros, Y Kim, JS Lewis… - JCI insight, 2019 - ncbi.nlm.nih.gov
Angiogenesis is a key process that allows nutrient uptake and cellular trafficking and is
coopted in cancer to enable tumor growth and metastasis. Recently, extracellular vesicles …

The VEGF pathway in cancer and disease: responses, resistance, and the path forward

MW Kieran, R Kalluri, YJ Cho - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago.
Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate …

[HTML][HTML] Molecular pathology of lung cancer: key to personalized medicine

L Cheng, RE Alexander, GT MacLennan… - Modern Pathology, 2012 - Elsevier
The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR)
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …